Enhanced Recovery Stem-Cell Transplantation: Multidisciplinary Efforts to Improve Outcomes in Older Adults Undergoing Hematopoietic Stem-Cell Transplant

PURPOSE: Older adults have unique risk factors for poor outcomes after hematopoietic stem-cell transplant (HSCT). We sought to determine the impact of our multidisciplinary supportive care program, Enhanced Recovery after stem-cell transplant (ER-SCT), on survival outcomes in patients age 65 years and older who underwent HSCT. PATIENTS AND METHODS: In this retrospective study, clinicodemographic data, nonrelapse mortality (NRM), overall survival (OS), and relapse were compared between 64 patients age 65 years and older who underwent allogeneic stem-cell transplant during ER-SCT program's first year, October 2017 through September 2018, and 140 historical controls age 65 years and older who underwent allogeneic HSCT, January 2015 through September 2017. RESULTS: In the ER-SCT cohort, 41% (26 of 64) of patients were women, and the median (range) age was 68 (65-74) years; in the control cohort, 38% (53 of 140) of patients were women, and the median (range) age was 67 (65-79) years. Hematopoietic cell transplant comorbidity index and donor type/cell source were similar between cohorts. The ER-SCT cohort had a lower 1-year NRM rate (13% v 26%, P = .03) and higher 1-year OS rate (74% v 53%, P = .007). Relapse rate did not differ significantly between cohorts. In multivariate analyses, ER-SCT was associated with improved 1-year NRM (hazard ratio, 0.4; 95% CI, 0.2 to 0.9; P = .02) and improved 1-year OS (hazard ratio, 0.5; 95% CI, 0.3 to 0.9; P = .03). CONCLUSION: A multidisciplinary supportive care program may improve NRM and OS in older patients undergoing allogeneic HSCT. Randomized studies are warranted to confirm this benefit and explore which program components most contribute to the improved outcomes.

[1]  D. Marin,et al.  Feasibility and Implementation of a Multimodal Supportive Care Program to Improve Outcomes in Older Patients Undergoing Allogeneic Stem Cell Transplantation. , 2021, Transplantation and cellular therapy.

[2]  M. Pasquini,et al.  Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. , 2020, Blood advances.

[3]  N. Kröger,et al.  Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation , 2020, Leukemia.

[4]  P. Hari,et al.  Current Use and Trends in Hematopoietic Cell Transplantation in the United States. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  R. Olin Delivering intensive therapies to older adults with hematologic malignancies: strategies to personalize care. , 2019, Blood.

[6]  P. Riedell,et al.  Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. , 2019, Blood advances.

[7]  S. Montoto,et al.  Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. , 2019, The Lancet. Haematology.

[8]  M. Perales,et al.  Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies , 2019, Bone Marrow Transplantation.

[9]  G. Abel,et al.  Gait speed, grip strength and clinical outcomes in older patients with hematologic malignancies. , 2019, Blood.

[10]  L. Jones,et al.  Impact of Sarcopenia on Adverse Outcomes After Allogeneic Hematopoietic Cell Transplantation. , 2019, Journal of the National Cancer Institute.

[11]  K. Rezvani,et al.  Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. , 2018, The Lancet. Haematology.

[12]  W. Wood,et al.  Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. , 2017, Blood.

[13]  M. Elzimaity,et al.  Nutritional status of allogeneic hematopoietic stem cell transplantation recipients: influencing risk factors and impact on survival , 2017, Supportive Care in Cancer.

[14]  M. Pasquini,et al.  Current use and trends in hematopoietic cell transplantation , 2017 .

[15]  Tetsuji Yamamoto,et al.  Clinical impact of sarcopenia and relevance of nutritional intake in patients before and after allogeneic hematopoietic stem cell transplantation , 2017, Journal of Cancer Research and Clinical Oncology.

[16]  Bradford J. Kim,et al.  The Impact of Postoperative Complications on a Timely Return to Intended Oncologic Therapy (RIOT): the Role of Enhanced Recovery in the Cancer Journey , 2016, International anesthesiology clinics.

[17]  S. Bhatia,et al.  Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients , 2015 .

[18]  K. Domen,et al.  Balance function in patients who had undergone allogeneic hematopoietic stem cell transplantation. , 2015, Gait & posture.

[19]  M. Sorror,et al.  Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  S. Mohile,et al.  Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. , 2014, Journal of geriatric oncology.

[21]  K. Gaensler,et al.  Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. , 2014, Journal of geriatric oncology.

[22]  O. Ljungqvist ERAS--enhanced recovery after surgery: moving evidence-based perioperative care to practice. , 2014, JPEN. Journal of parenteral and enteral nutrition.

[23]  R. Stauder,et al.  The relevance of a geriatric assessment for elderly patients with a haematological malignancy--a systematic review. , 2014, Leukemia research.

[24]  K. van Besien,et al.  Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  K. Domen,et al.  Prevalence of sarcopenia and relevance of body composition, physiological function, fatigue, and health-related quality of life in patients before allogeneic hematopoietic stem cell transplantation , 2012, Supportive Care in Cancer.

[26]  K. Domen,et al.  Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation , 2012, Supportive Care in Cancer.

[27]  P. Hari,et al.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. , 2011, JAMA.

[28]  Michael Boeckh,et al.  Reduced mortality after allogeneic hematopoietic-cell transplantation. , 2010, The New England journal of medicine.

[29]  J Hermans,et al.  Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation , 1998, The Lancet.